• Explore /
  • Poster
  • / A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).

A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).

Abstract Poster

Authors

null

Kenro Hirata

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Kenro Hirata , Yasuo Hamamoto , Hirokazu Shoji , Hiroki Hara , Chihiro Kondoh , Hisateru Yasui , Takeshi Kajiwara , Eishi Baba , Takayuki Ando , Naotoshi Sugimoto , Naohiro Okano , Hisato Kawakami , Hiroo Katsuya , Michitaka Nagase , Toshikazu Moriwaki , Kenichi Yoshimura , Masahiko Ando , Kentaro Yamazaki , Shuichi Hironaka , Kei Muro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

jRCTs031180022

DOI

10.1200/JCO.2022.40.4_suppl.280

Abstract #

280

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Mashiro Okunaka

First Author: Hiroo Katsuya

First Author: Mingfang Xu

First Author: Peter C. Thuss-Patience